Author:
Moots Robert,Azevedo Valderilio,Coindreau Javier L.,Dörner Thomas,Mahgoub Ehab,Mysler Eduardo,Scheinberg Morton,Marshall Lisa
Publisher
Springer Science and Business Media LLC
Reference119 articles.
1. European Medicines Agency. Guideline on similar biological medicinal products. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf . Accessed 31 Mar 2016.
2. United States Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry. 2015. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/UCM291128.pdf . Accessed 31 Mar 2016.
3. World Health Organization. Guidelines on evaluation of similar biotherapeutic products (SBPs). 2010. http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf . Accessed 31 Mar 2016.
4. Scheinberg MA, Kay J. The advent of biosimilar therapies in rheumatology–“O Brave New World”. Nat Rev Rheumatol. 2012;8:430–6.
5. Mysler E, Pineda C, Horiuchi T, Singh E, Mahgoub E, Coindreau J, et al. Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology. Rheumatol Int. 2016;36:613–25. doi: 10.1007/s00296-016-3444-0 .
Cited by
80 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献